Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07410624 · ClinicalTrials.gov registry record

Augmented Renal Clearance in Neurocritical Care

A clinical trial of Ischemic Stroke and Intracerebral Hemorrhage, sponsored by University of Alberta.

Recruiting
Registry status
512
Enrollment target
3
Study locations

NCT07410624: Recruiting study of Ischemic Stroke and Intracerebral Hemorrhage, sponsored by University of Alberta.

NCT07410624 is a study of Ischemic Stroke and Intracerebral Hemorrhage that is actively recruiting participants, run by University of Alberta. The registered enrollment target is 512 participants, below the 1,456-participant average among 66 other Ischemic Stroke trials with a reported enrollment target (65% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07410624, a study of Ischemic Stroke and Intracerebral Hemorrhage, is actively recruiting participants, sponsored by University of Alberta.

RECRUITING
Registry status
512 participants
Enrollment target
3
Study locations

Study Summary

Stroke, severe brain injury, uncontrolled seizures and brain infections are the most common life-threatening neurological illnesses in the world with an estimated combined annual hospital management cost of up to 44 billion dollars. Seizures and infections are common complications following acute neurological illnesses and contribute significantly to poor outcomes if not promptly treated with appropriately dosed anti-seizure medications and antibiotics, respectively. Limited research suggested that many of those patients present with a phenomenon called augmented renal clearance (ARC) or, in other words, enhanced kidney function. ARC may have a significant influence on how medications are removed from the body potentially resulting in insufficient doses and treatment failure. Therefore, patients with ARC require higher medication doses; however, ARC is largely undetected using kidney assessment methods currently used in practice. In addition, it is not clear how medications should be dosed in those with ARC. The majority of ARC research has not focused on patients with life-threatening neurological illnesses. Thus, clinicians are likely under-dosing vital medications in those patients, and completely unaware. There is an immediate need to address the gap in knowledge. Therefore, this research aims to characterize the phenomenon of ARC in patients with life-threatening neurological illnesses through identifying the frequency, duration, contributing factors and clinical impact of ARC. Adult patients admitted to the neurosciences intensive care unit for life-threatening neurological illnesses will be enrolled in the study. Urine and blood samples wil be collected from participants to determine the presence of ARC and identify its contributing factors. In addition, blood samples will be collected from participants treated with select antibiotics and anti-seizure medications to determine their concentration and propose dose adjustment in those with ARC. This research is

Primary Outcome

Participants' CrCl will be measured using the 8-h urine collection method (8h urine collection method provides best representation of 24h CrCl and is less labor intensive). Once the patient is enrolled in the study, the first 8-hour urine collection will be obtained. Concurrent morning SCr will be collected and measured CrCl will be calculated

Study Locations (3)

Kentucky

  • UK HealthCare - Lexington

Ohio

  • The Ohio State University Wexner Medical Center - Columbus

Alberta

  • University of Alberta Hospital - Edmonton

Trial Details

FieldValue
Enrollment Target 512 participants
Start Date 2021-10-01
Est. Completion 2026-09-30
University of Alberta

19 total trials

What NCT07410624 shows while recruiting

NCT07410624 is an observational study that tracks outcomes without assigning an intervention. The registered 512 participants enrollment target is mid-sized for trials with a published cap, below the 1,456-participant average among 66 other Ischemic Stroke trials with a reported enrollment target (65% lower).

The record links to 7 conditions, with Ischemic Stroke appearing as the primary indexed condition, and to 0 interventions.

NCT07410624 reports a single indexed study location in Kentucky, Ohio, Alberta.

Frequently Asked Questions

What is clinical trial NCT07410624 about?

NCT07410624 is a clinical study titled "Augmented Renal Clearance in Neurocritical Care". Stroke, severe brain injury, uncontrolled seizures and brain infections are the most common life-threatening neurological illnesses in the world with an estimated combined annual hospital management cost of up to 44 billion dollars. Seizures and infections are common complications following acute ne...

What is the current status of trial NCT07410624?

This trial is currently recruiting. The enrollment target is 512 participants. The study started on 2021-10-01. Estimated completion is 2026-09-30.

What conditions does trial NCT07410624 study?

This clinical trial studies the following conditions: Ischemic Stroke, Intracerebral Hemorrhage, TBI (Traumatic Brain Injury), Status Epilepticus, Subarachnoid Hemorrhage, Aneurysmal.

Who is sponsoring clinical trial NCT07410624?

This trial is sponsored by University of Alberta, which has 19 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07410624 being conducted?

This trial has 3 study locations across Kentucky, Ohio, Alberta. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Ischemic Stroke

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT07410624's enrollment target sits among peer trials

512 16th of 66 higher than 51 of 66 other Ischemic Stroke trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Ischemic Stroke trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05005403 · 512 participants · Phase 1

    Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors, Receiving Intravenous (IV) Infusion of Azirkitug (ABBV-514) Alone or in Combination With Budigalimab or Bevacizumab

  • NCT05337410 · 512 participants · NA

    YES: Innovative Discussion for Engagement, Achievement, and Service

  • NCT06096259 · 512 participants · Phase 2

    Preventing Injured Knees From osteoArthritis: Severity Outcomes

  • NCT05691244 · 514 participants · Phase 3

    Assess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Ischemic Stroke

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT07410624, the US trial registry maintained by the National Library of Medicine. NCT07410624 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.